Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have a current diagnosis of schizophrenia.
Increase in symptoms over the past 2-4 weeks.
Willing to remain inpatients for the duration of the trial.
You may not be if
Subjects with a current DSM-IV axis I diagnosis other than schizophrenia
Subjects who meet the DSM-IV criteria for psychoactive substance abuse and dependence
Subjects with a history of treatment resistant schizophrenia
Females of childbearing potential
Clareo Health | Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia
